- Mechanism
- Stimulates lipolysis via beta-3 adrenergic receptors
- Typical research dose
- 250-500 mcg/day subcutaneous (research)
- Route
- Subcutaneous
- Half-life
- Short (estimated <1 hour)
- Legal status
- Research Only / WADA Prohibited
Overview
AOD-9604 is a synthetic peptide fragment derived from the C-terminus of human growth hormone (hGH), specifically isolating amino acids 176-191. It is designed to harness the lipolytic properties of hGH to stimulate fat breakdown and inhibit the conversion of dietary materials into body fat. Because it isolates the fat-burning mechanism without triggering IGF-1 release, the AOD-9604 peptide offers a targeted approach to obesity research and metabolic enhancement without the insulin resistance or cellular growth risks associated with full-length hGH.
Potential Benefits
- Targeted Fat Loss: Research indicates that the AOD-9604 peptide stimulates lipolysis and inhibits lipogenesis, effectively reducing body fat stores in animal models Wilding J, 2004.
- Metabolic Enhancement: The peptide enhances overall metabolic function by mimicking the natural fat-regulating mechanisms of human growth hormone Halford JC, 2006.
- Cartilage and Joint Repair: Emerging studies suggest AOD-9604 may promote cartilage regeneration and assist in managing osteoarthritis when combined with other therapies Rahman OF et al., 2026.
- Stable Blood Sugar Levels: Unlike full-length hGH, AOD-9604 benefits include fat reduction without negatively affecting blood glucose levels or inducing insulin resistance Bayés M et al., 2005.
- No Unwanted Cellular Growth: Clinical evaluations demonstrate that the peptide does not stimulate IGF-1 production, avoiding the risks of unwanted cellular proliferation Bayés M et al., 2003.
Where to Buy AOD-9604
Research compound. AOD-9604 is a research chemical, typically not FDA-approved for human consumption. Sale or use for human consumption may be illegal in your jurisdiction.
No compensation. PeptideStack does not endorse, verify, or receive compensation from any vendor. No affiliate or referral relationships.
Verify third-party COAs and consult a qualified healthcare provider before using any compound.
Side Effects
Common side effects:
- Injection site redness or irritation
- Mild headaches
- Flushing or warmth in the face
- Temporary fatigue or lethargy
- Upset stomach or mild nausea
Rare or serious side effects:
- Allergic reactions at the injection site
- Palpitations or rapid heartbeat
- Dizziness upon standing
- Unexplained joint stiffness
AOD-9604 is not FDA-approved and is intended for research purposes only. Consult a qualified healthcare provider before use.
Mechanism of Action
Lipolytic activation is the primary mechanism by which the AOD-9604 peptide exerts its effects, specifically targeting beta-3 adrenergic receptors to stimulate the breakdown of triglycerides into free fatty acids. This targeted action mimics the natural fat-burning pathways of human growth hormone but remains isolated to adipose tissue, preventing systemic endocrine disruption.
Inhibition of lipogenesis further enhances its efficacy by preventing the body from converting dietary carbohydrates and lipids into new fat stores. Because it lacks the specific amino acid sequences responsible for binding to the hGH receptor that triggers IGF-1 release, AOD-9604 does not promote cellular growth or alter insulin sensitivity, making it highly specific for metabolic regulation.
Origin & History
Discovery and development of AOD-9604 began in the late 1990s by researchers at Monash University in Australia, who sought to identify the specific region of the human growth hormone molecule responsible for fat metabolism. They successfully isolated the C-terminal fragment (amino acids 176-191) and modified it with an additional tyrosine residue to stabilize the molecule, creating a potent synthetic peptide.
Regulatory milestones include extensive clinical trials by Metabolic Pharmaceuticals in the early 2000s, which investigated its potential as a mainstream anti-obesity drug Bayés M et al., 2003. Although it reached Phase IIb human clinical trials and demonstrated an excellent safety profile, it is currently designated as a research-only chemical and is actively monitored in sports doping controls Cox HD et al., 2015.